3.44
Precedente Chiudi:
$3.37
Aprire:
$3.32
Volume 24 ore:
827.34K
Relative Volume:
1.30
Capitalizzazione di mercato:
$78.09M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-1.8201
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
+17.01%
1M Prestazione:
+101.17%
6M Prestazione:
+56.36%
1 anno Prestazione:
+194.02%
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Confronta IMRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
IMRX
Immuneering Corp
|
3.44 | 78.09M | 317.00K | -53.47M | -49.31M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2024-03-15 | Downgrade | Jefferies | Buy → Hold |
2024-03-15 | Reiterato | Needham | Buy |
2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-12-01 | Iniziato | Needham | Buy |
2023-06-26 | Ripresa | Oppenheimer | Outperform |
2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2023-03-30 | Iniziato | Mizuho | Neutral |
2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
2022-04-01 | Iniziato | Oppenheimer | Outperform |
2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus
Immuneering Corp SEC 10-Q Report - TradingView
Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan
IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan
Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com
What technical indicators reveal about IMRX stock - uspostnews.com
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World
Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan
Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World
Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter
Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World
Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks
Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan
Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks
Immuneering Corp SEC 10-K Report - TradingView
Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com
Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan
Immuneering appoints Igor Matushansky as CMO - The Pharma Letter
Immuneering appoints new Chief Medical Officer - Investing.com
Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immuneering Corp Azioni (IMRX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 20 '25 |
Buy |
2.70 |
7,415 |
20,020 |
353,311 |
Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 23 '25 |
Buy |
2.43 |
6,007 |
14,596 |
359,318 |
Brakewood Harold Eugene | Chief Business Officer |
Jun 20 '25 |
Buy |
2.53 |
1,900 |
4,804 |
5,800 |
Feinberg Peter | Director |
Jun 18 '25 |
Buy |
2.53 |
25,000 |
63,188 |
136,766 |
Zeskind Benjamin J. | PRESIDENT AND CEO |
Jun 18 '25 |
Buy |
2.39 |
21,000 |
50,144 |
2,302,852 |
Schall Thomas J. | Director |
Jun 17 '25 |
Buy |
2.21 |
40,485 |
89,278 |
43,385 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):